128 related articles for article (PubMed ID: 28871998)
21. Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma.
Clement SC; van Rijn RR; van Eck-Smit BL; van Trotsenburg AS; Caron HN; Tytgat GA; van Santen HM
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):706-15. PubMed ID: 25512056
[TBL] [Abstract][Full Text] [Related]
22. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients.
Garaventa A; Bellagamba O; Lo Piccolo MS; Milanaccio C; Lanino E; Bertolazzi L; Villavecchia GP; Cabria M; Scopinaro G; Claudiani F; De Bernardi B
Br J Cancer; 1999 Dec; 81(8):1378-84. PubMed ID: 10604736
[TBL] [Abstract][Full Text] [Related]
23. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma.
Taggart D; Dubois S; Matthay KK
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):403-18. PubMed ID: 19088694
[TBL] [Abstract][Full Text] [Related]
24. Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma.
Howard JP; Maris JM; Kersun LS; Huberty JP; Cheng SC; Hawkins RA; Matthay KK
Pediatr Blood Cancer; 2005 Mar; 44(3):232-9. PubMed ID: 15490487
[TBL] [Abstract][Full Text] [Related]
25. Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy.
Modak S; Pandit-Taskar N; Kushner BH; Kramer K; Smith-Jones P; Larson S; Cheung NK
Pediatr Blood Cancer; 2008 Jun; 50(6):1271-3. PubMed ID: 17973318
[TBL] [Abstract][Full Text] [Related]
26. Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.
Matthay KK; Quach A; Huberty J; Franc BL; Hawkins RA; Jackson H; Groshen S; Shusterman S; Yanik G; Veatch J; Brophy P; Villablanca JG; Maris JM
J Clin Oncol; 2009 Mar; 27(7):1020-5. PubMed ID: 19171714
[TBL] [Abstract][Full Text] [Related]
27. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.
Yanik GA; Levine JE; Matthay KK; Sisson JC; Shulkin BL; Shapiro B; Hubers D; Spalding S; Braun T; Ferrara JL; Hutchinson RJ
J Clin Oncol; 2002 Apr; 20(8):2142-9. PubMed ID: 11956276
[TBL] [Abstract][Full Text] [Related]
28. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
29. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
Castellani MR; Chiti A; Seregni E; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):77-87. PubMed ID: 10932604
[TBL] [Abstract][Full Text] [Related]
30. 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma.
DuBois SG; Matthay KK
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):53-65. PubMed ID: 23474635
[TBL] [Abstract][Full Text] [Related]
31. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine.
Garaventa A; Gambini C; Villavecchia G; Di Cataldo A; Bertolazzi L; Pizzitola MR; De Bernardi B; Haupt R
Cancer; 2003 Mar; 97(5):1332-8. PubMed ID: 12599242
[TBL] [Abstract][Full Text] [Related]
32. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma.
van Santen HM; de Kraker J; van Eck BL; de Vijlder JJ; Vulsma T
Cancer; 2002 Apr; 94(7):2081-9. PubMed ID: 11932913
[TBL] [Abstract][Full Text] [Related]
33. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.
Quach A; Ji L; Mishra V; Sznewajs A; Veatch J; Huberty J; Franc B; Sposto R; Groshen S; Wei D; Fitzgerald P; Maris JM; Yanik G; Hawkins RA; Villablanca JG; Matthay KK
Pediatr Blood Cancer; 2011 Feb; 56(2):191-201. PubMed ID: 20830775
[TBL] [Abstract][Full Text] [Related]
34. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.
DuBois SG; Matthay KK
Nucl Med Biol; 2008 Aug; 35 Suppl 1(Suppl 1):S35-48. PubMed ID: 18707633
[TBL] [Abstract][Full Text] [Related]
35. Treatment with meta-[131I]iodobenzylguanidine and cisplatin in stage IV neuroblastoma.
Mastrangelo S; Tornesello A; Diociaiuti L; Riccardi R; Rufini V; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):69-71. PubMed ID: 9002754
[TBL] [Abstract][Full Text] [Related]
36. [Thyroid dysfunction due to 131I-metaiodobenzylguanidine in patients with neuroblastoma].
Garrido Magaña E; Silva Estrada JA; Nishimura Meguro E; Rivera Hernández AJ; Zurita Cruz JN
Rev Chil Pediatr; 2020 Jun; 91(3):379-384. PubMed ID: 32730518
[TBL] [Abstract][Full Text] [Related]
37. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
[TBL] [Abstract][Full Text] [Related]
38. Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures.
Evans AC; Setzkorn T; Edmondson DA; Segelke H; Wilson PF; Matthay KK; Granger MM; Marachelian A; Haas-Kogan DA; DuBois SG; Coleman MA
Radiat Res; 2022 Feb; 197(2):101-112. PubMed ID: 34673986
[TBL] [Abstract][Full Text] [Related]
39. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
[TBL] [Abstract][Full Text] [Related]
40. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.
Yanik GA; Villablanca JG; Maris JM; Weiss B; Groshen S; Marachelian A; Park JR; Tsao-Wei D; Hawkins R; Shulkin BL; Jackson H; Goodarzian F; Shimada H; Courtier J; Hutchinson R; Haas-Koga D; Hasenauer CB; Czarnecki S; Katzenstein HM; Matthay KK
Biol Blood Marrow Transplant; 2015 Apr; 21(4):673-81. PubMed ID: 25639769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]